Genetic Variation of CYP3A5 Influences Paclitaxel/Carboplatin-Induced Toxicity in Chinese Epithelial Ovarian Cancer Patients
Genetic Variation of CYP3A5 Influences Paclitaxel/Carboplatin-Induced Toxicity in Chinese Epithelial Ovarian Cancer Patients
复制标题
CYP3A5 的遗传变异影响紫杉醇/卡铂在中国上皮性卵巢癌患者中引起的毒性
DOI：
10.1002/jcph.587
复制
发表时间：
2016-03-01
影响因子：
2.9
通讯作者：
Zhou, Hong-Hao
中科院分区：
文献类型：
--
作者：
Hu, Lei;Lv, Qiao-Li;Zhou, Hong-Hao
铂类与紫杉烷类联合化疗是卵巢癌的一线治疗方案。这些药物的剂量限制性毒性包括神经病变、白细胞减少症和中性粒细胞减少症，但它们表现出很大的个体间差异。本研究旨在探讨CYP 3A 5基因多态性与紫杉醇/卡铂联合化疗毒性的关系。招募了75例上皮性卵巢癌患者。联合化疗后进行基因型分析，并根据通用毒性标准评价毒性反应。骨髓抑制与CYP 3A 5 *3基因型之间存在显著相关性。CYP 3A 5 *3/* I患者发生白细胞减少症的风险显著增高（P
Combination chemotherapy with platinum and taxane is the first-line treatment for ovarian cancer. The dose-limiting toxicities of these drugs include neuropathy, leukopenia, and neutropenia, but they exhibit substantial interindividual variability. This study investigated the relationship between CYP3A5 polymorphisms and paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients. Seventy-five patients with epithelial ovarian cancer were recruited. After combination chemotherapy, genotype analysis was conducted, and toxic effects were evaluated according to the Common Toxicity Criteria. A significant association was found between myelosuppression and the CYP3A5*3 genotype. CYP3A5*3/* I patients showed a significantly higher risk of developing leukopenia (P